Cellco Inc. has been awarded a $50,000 Phase I small businessinnovation research (SBIR) grant to investigate and develop animproved method of bone marrow transplantation therapy forcancer.
The Germantown, Md., company will expand research efforts inthe removal of cancer cells from bone marrow. This wouldincrease the safety of autologous bone marrow transplants forpatients with advanced cancer by reducing the risk ofreinfusing the patient with malignant cells.
Cellco is engaged in the research and development of artificialcapillary cell culture systems for use in human cellulartherapies.
(c) 1997 American Health Consultants. All rights reserved.